Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 26, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - June 26, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

6/26/17 - "Synergistic Pharmaceutical Combination for the Treatment of Squamous Cell Carcinoma of Head and Neck" in Patent Application Approval Process (USPTO...
"Synergistic Pharmaceutical Combination for the Treatment of Squamous Cell Carcinoma of Head and Neck" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Cancer Gene Therapy Week A patent application by the inventors Agarwal, Veena; Balakrishnan, Arun; Periyasamy, Giridharan, filed on July 8, 2016, was made available
6/26/17 - "TREATMENT OF CNS DISORDERS WITH Trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE" in Patent Application Approval Process (USPTO...
By a News Reporter-Staff News Editor at Mental Health Weekly Digest A patent application by the inventors JERUSSI, Thomas; FANG, Qun Kevin; CURRIE, Mark G., filed on October 20, 2016, was made available online on June 15, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assi
6/26/17 - 'Pharma Bro' defies advice to keep quiet before fraud trial
Even with his federal securities fraud trial set to begin Monday, Martin Shkreli has blatantly defied his attorneys' advice to lay low. He went on Twitter to label members of Congress "imbeciles" for demanding to know why his company, Turing Pharmaceuticals, raised the price of Daraprim, a drug used to treat toxoplasmosis and HIV, from $13.50 to $7
6/26/17 - AAM Biosimilars Council Praises Unanimous Supreme Court Ruling That Will Accelerate Patient Access to Biosimilar Medicines
By a News Reporter-Staff News Editor at Pharma Business Week The Association for Accessible Medicines applauded the U.S. Supreme Court's decision this week in Sandoz Inc. v. The Biosimilars Council, a division of the AAM, filed an amicus brief in the case consistent with the Court's ruling, recognizing delaying competition would cost patients, in
6/26/17 - Abbott Laboratories Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on June 9, 2017. The SEC file number is 0001179110-17-008829.. A U.S. Securities and Exchange Commission filing is a f
6/26/17 - Abbott Laboratories Files SEC Form 4/A, Statement of Changes in Beneficial Ownership of Securities (Jun. 13, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on June 13, 2017. The SEC file number is 0001179110-17-008980.. A U.S. Securities and Exchange Commission filing is a
6/26/17 - Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC
By a News Reporter-Staff News Editor at Pharma Business Week Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals, Inc. announced that the Registration Statement on Form S-4 has been declared effective by the Securities and Exchange Commission on June 13, 2017. The special meeting of the OGXI stockholders will be held on August 1, 2017, at 9
6/26/17 - Acorda Therapeutics Inc. Files SEC Form 8-K, Current Report (Jun. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acorda Therapeutics Inc. was posted on June 9, 2017. The SEC file number is 0001564590-17-012369.. A U.S. Securities and Exchange Commission filing i
6/26/17 - Actinium Pharmaceuticals, Inc. Files SEC Form 8-K, Current Report (Jun. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Actinium Pharmaceuticals, Inc. was posted on June 8, 2017. The SEC file number is 0001213900-17-006261.. A U.S. Securities and Exchange Commission fi
6/26/17 - Actinium Pharmaceuticals, Inc. Files SEC Form 8-K, Current Report (Jun. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Actinium Pharmaceuticals, Inc. was posted on June 9, 2017. The SEC file number is 0001213900-17-006302.. A U.S. Securities and Exchange Commission fi
6/26/17 - Adamis Pharmaceuticals Corp. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 12, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamis Pharmaceuticals Corp. was posted on June 12, 2017. The SEC file number is 0001387131-17-003204.. A U.S. Securities and Exchange Commission fil
6/26/17 - Adamis Pharmaceuticals Corp. Files SEC Form 8-K, Current Report (Jun. 12, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamis Pharmaceuticals Corp. was posted on June 12, 2017. The SEC file number is 0001387131-17-003201.. A U.S. Securities and Exchange Commission fil
6/26/17 - Aerie Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aerie Pharmaceuticals Inc. was posted on June 9, 2017. The SEC file number is 0001209191-17-038854.. A U.S. Securities and Exchange Commission filing
6/26/17 - Aerie Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aerie Pharmaceuticals Inc. was posted on June 9, 2017. The SEC file number is 0001193125-17-200009.. A U.S. Securities and Exchange Commission filing
6/26/17 - Agile Therapeutics Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agile Therapeutics Inc. was posted on June 9, 2017. The SEC file number is 0001104659-17-038460.. A U.S. Securities and Exchange Commission filing is
6/26/17 - Agile Therapeutics Inc. Files SEC Form 8-K, Current Report (Jun. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agile Therapeutics Inc. was posted on June 8, 2017. The SEC file number is 0001104659-17-038163.. A U.S. Securities and Exchange Commission filing is
6/26/17 - Agios Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agios Pharmaceuticals Inc. was posted on June 8, 2017. The SEC file number is 0001209191-17-038521.. A U.S. Securities and Exchange Commission filing
6/26/17 - Alexion Pharmaceuticals Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities (Jun. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alexion Pharmaceuticals Inc. was posted on June 9, 2017. The SEC file number is 0000899866-17-000129.. A U.S. Securities and Exchange Commission fili
6/26/17 - Alexion Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alexion Pharmaceuticals Inc. was posted on June 9, 2017. The SEC file number is 0000899866-17-000134.. A U.S. Securities and Exchange Commission fili
6/26/17 - Alexion Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 13, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alexion Pharmaceuticals Inc. was posted on June 13, 2017. The SEC file number is 0000899866-17-000138.. A U.S. Securities and Exchange Commission fil
6/26/17 - Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder
By a News Reporter-Staff News Editor at Mental Health Weekly Digest Alkermes plc announced the initiation of study 217, a phase 3 b trial of ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder. The company also reiterated plans to submit a New Drug Appli
6/26/17 - Alkermes Plc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alkermes Plc. was posted on June 8, 2017. The SEC file number is 0001127602-17-020961.. A U.S. Securities and Exchange Commission filing is a formal
6/26/17 - Alkermes Plc. Files SEC Form CT ORDER, Confidential Treatment Order (Jun. 13, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alkermes Plc. was posted on June 12, 2017. The SEC file number is 9999999997-17-006982.. A U.S. Securities and Exchange Commission filing is a formal
6/26/17 - Amphastar Pharmaceuticals, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 12, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amphastar Pharmaceuticals, Inc. was posted on June 12, 2017. The SEC file number is 0001104659-17-038770.. A U.S. Securities and Exchange Commission
6/26/17 - Amphastar Pharmaceuticals, Inc. Files SEC Form 8-K, Current Report (Jun. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amphastar Pharmaceuticals, Inc. was posted on June 8, 2017. The SEC file number is 0001297184-17-000020.. A U.S. Securities and Exchange Commission f
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415